

New Products - Opsumit

Opsumit (**macitentan**) is a dual ETA and ETB endothelin receptor antagonist that prevents the binding of endothelin (ET)-1 to its receptors. Macitentan displays high affinity for and sustained occupancy of the ET receptors in human pulmonary arterial smooth muscle cells and has physicochemical properties favouring penetration into lung tissue, particularly in disease conditions. Opsumit, as monotherapy or in combination with approved pulmonary arterial hypertension treatments (phosphodiesterase-5 inhibitors or inhaled prostanoids), is indicated for the treatment of the following conditions in patients with WHO functional class II, III or IV symptoms. Idiopathic pulmonary arterial hypertension; heritable pulmonary arterial hypertension; pulmonary arterial hypertension associated with connective tissue disease; and pulmonary arterial hypertension associated with congenital heart disease with repaired shunts. Opsumit is contraindicated in women who are or may become pregnant; women of childbearing potential who are not using reliable contraception (women must not become pregnant for at least 3 months after stopping treatment with Opsumit); hypersensitivity to the active substance or to any of the excipients; patients with severe hepatic impairment (with or without cirrhosis) and in patients with baseline values of hepatic aminotransferases (aspartate aminotransferase and/or alanine aminotransferase) greater than 3 times the upper limit of normal. Opsumit is available as 10 mg film coated tablets in blister packs of 30's.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.